Anifrolumab for Continued Treatment Access

(ROSY-S Trial)

This trial provides continued access to anifrolumab for individuals who used it in a previous study, assessing its ongoing benefits. It focuses on evaluating the long-term safety and tolerability of the treatment. The trial includes participants who completed the earlier anifrolumab study and found it beneficial. The primary goal is to ensure the treatment remains safe while continuing to support those in need. Participants will receive the treatment as before, with close monitoring for any side effects. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential approval of a promising treatment.

The trial protocol does not specify if you need to stop your current medications. However, if you are taking any medications that were prohibited in the parent study, you may not be eligible to participate.

Research has shown that anifrolumab is generally safe for people with systemic lupus erythematosus (SLE). Studies have found that most people do not experience serious side effects, though some have reported side effects like shingles.

In everyday use and long-term studies, anifrolumab continues to demonstrate good safety results. It is already approved for treating SLE, indicating it has met strict safety standards. While some side effects are known, they are usually manageable and do not outweigh the benefits for many patients.

Unlike the standard treatments for lupus, which often involve broad immunosuppressants, anifrolumab works by specifically targeting the type I interferon pathway, a key driver of inflammation in lupus. This targeted mechanism of action allows for potentially better control of symptoms with fewer side effects. Researchers are excited about anifrolumab because it offers hope for more precise and effective treatment, improving the quality of life for patients with lupus.

Research has shown that anifrolumab can help treat systemic lupus erythematosus (SLE), a condition affecting the immune system. In a long-term study, patients experienced improvements in overall symptoms, including better kidney function. Another study found that after four years, about 37% of patients taking anifrolumab had low disease activity, compared to 17% of those on a placebo. The treatment has been well-tolerated, indicating it is generally safe for patients. Overall, these findings suggest that anifrolumab can significantly help manage lupus symptoms over time.⁶⁷⁸⁹¹⁰